English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/101475
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorBarderas, Rodrigo-
dc.contributor.authorVillar-Vázquez, Roi-
dc.contributor.authorFernandez-Aceñero, M. Jesús-
dc.contributor.authorBabel, Ingrid-
dc.contributor.authorPeláez-García, Alberto-
dc.contributor.authorTorres, Sofía-
dc.contributor.authorCasal, J. Ignacio-
dc.date.issued2013-10-15-
dc.identifier.citationScientific Reports 3:2938es_ES
dc.identifier.issn2045-2322-
dc.identifier.urihttp://hdl.handle.net/10261/101475-
dc.description7 p.-4 fig.es_ES
dc.description.abstractAlthough autoantibody detection has been proposed for diagnosis of colorectal cancer, little is known about their initial production and development correlation with cancer progression. Azoxymethane/dextran sodium sulfate (AOM/DSS)-treated mice developed colon adenocarcinoma in the distal colon similar to human sporadic colon cancer. We assessed this model together with AOM and DSS-only models for their applicability to early detection of cancer. All AOM/DSS-treated mice produced autoantibodies to tumor-associated antigens analogous to those observed in human colon cancer patients. Autoantibody response was related to tumor antigen overexpression. Cancer autoantibodies were detected 21 days after starting treatment, when no malignant histopathological features were detectable, and they increased according to tumor progression. When carcinogenesis was induced separately by AOM or DSS, only those mice that developed malignant lesions produced significant levels of autoantibodies. These findings demonstrate that autoantibody development is an early event in tumorigenesis and validates its use for preclinical colon cancer diagnosis.es_ES
dc.description.sponsorshipThis study was supported by grant BIO2012-31023 from the MINECO, a grant to established research groups of the Asociación Española Contra el Cancer and the grant S2010/BMD-2344/Colomics2 from Comunidad de Madrid.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Groupes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rightsopenAccesses_ES
dc.titleSporadic colon cancer murine models demonstrate the value of autoantibody detection for preclinical cancer diagnosises_ES
dc.typeartículoes_ES
dc.identifier.doi10.1038/srep02938-
dc.description.peerreviewedPeer reviewedes_ES
dc.relation.publisherversionhttp://dx.doi.org/10.1038/srep02938es_ES
dc.identifier.e-issn2045-2322-
dc.rights.licensehttp://creativecommons.org/licenses/by-nc-nd/3.0es_ES
dc.relation.csices_ES
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
SCIENTIFIC REPORTS I. Casal.pdf2,45 MBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.